Pioneering for patients

We discover. We dare. We care.

Who we are

Galapagos NV discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in clinical development in multiple diseases. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications.

Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

Our mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary cells and patient cells, the company discovers which proteins (‘targets’) play a key role in causing diseases such as rheumatoid arthritis, inflammatory bowel disease and fibrosis. Galapagos then aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease. This approach addresses the disease rather than just treating the symptoms.

Our aim is to make a lasting positive contribution to society through discovery of breakthrough therapies for diseases with large unmet medical need.

Galapagos has more than 1,200 employees worldwide, with sites in Belgium (international headquarters), the Netherlands, France, Germany, Italy, Spain, Switzerland, the UK and the US.

How we operate

We aim to discover and develop medicines to contribute to the quality of life of patients around the world. These patients and their physicians place their trust in us and our medicines. Trust comes with responsibility. Therefore, we apply high ethical standards in all of our business areas. Everyone working for and with Galapagos is expected to adhere to these standards.

Ansicht des Baloise Park

The Baloise Park

Our History

Galapagos was founded in 1999 as a joint venture between Crucell and Tibotec. In May 2005, the Company listed on Euronext Brussels and Amsterdam (ticker symbol: GLPG). In 2006, Galapagos acquired ProSkelia in Romainville, France, obtaining R&D operations there. In 2010, Galapagos acquired the Zagreb research operations from GSK; this site became Fidelta, a drug discovery fee-for-service business within the Galapagos group. Fidelta was subsequently acquired by Selvita in 2020.

In 2014 Galapagos sold fee-for-service businesses BioFocus and Argenta to Charles River Laboratories International, Inc., giving Galapagos a sole focus on the development and execution of a broad and deep R&D pipeline based on novel mechanisms-of-action. 

Galapagos listed on the US NASDAQ (ticker symbol: GLPG) in May 2015.

In 2015, Galapagos signed a collaboration agreement with Gilead for the development and commercialization of filgotinib.

In 2019, Galapagos entered into a transformative 10-year global research and development collaboration with Gilead.

In 2020, Jyseleca® was granted marketing authorization for the treatment of rheumatoid arthritis in the EU and Japan, marking Galapagos’ transition to commercial-stage biotech.

Contact

Galapagos GmbH
Baloise Park West
22. und 23. OG
Aeschengraben 20
4051 Basel
Switzerland
Email: admin_bas [at] glpg.com